Rothman L P, Harvald T B, Overgaard H
Department of Surgery, KAS Glostrup, Copenhagen, Denmark.
Eur J Surg. 1996 Sep;162(9):691-4.
To evaluate the suitability of currently applied mammographic criteria for the early diagnosis of subclinical tumours by comparing radiological findings with the final histological diagnosis.
Open study.
District hospital, Denmark.
151 Women who underwent needle biopsy of 161 occult breast lesions that had been diagnosed by mammography during the period 1986-90.
Definitive operation if frozen section at the time of needle biopsy indicated malignancy. Radiographic examination of the specimen ensured that the abnormal area had been excised.
Correlation of mammographic and histological findings.
Eight foci showed carcinoma in situ and 33 invasive carcinoma; 10 of the 33 had lymph node metastases. Foci with mammographic masses had a significantly higher risk of malignancy than those without (25/70, 37%, compared with 8/91, 17%, p = 0.005). Spiculated foci with clustered calcifications had the highest risk of malignancy (6/11, 54%). 16/87 foci in women less than 50 years old contained malignant disease compared with 25/74 in women aged 50 or more (p = 0.04). A fifth of the frozen sections contributed nothing to the diagnosis. The incidence of malignant disease in impalpable lesions of a quarter is similar to the reported incidence in palpable mammary tumours, but metastases at the time of diagnosis are appreciably less common (30% compared with 50%).
The currently applied mammographic criteria are particularly helpful to patients under the age of 50.
通过比较放射学检查结果与最终组织学诊断结果,评估当前应用的乳腺钼靶标准对亚临床肿瘤早期诊断的适用性。
开放性研究。
丹麦地区医院。
151名女性,她们在1986年至1990年期间对经乳腺钼靶检查诊断出的161处隐匿性乳腺病变进行了针吸活检。
如果针吸活检时的冰冻切片显示为恶性,则进行确定性手术。对标本进行放射学检查以确保切除了异常区域。
乳腺钼靶检查结果与组织学检查结果的相关性。
8个病灶显示原位癌,33个为浸润性癌;33例中有10例发生淋巴结转移。有乳腺钼靶肿块的病灶发生恶性病变的风险显著高于无肿块的病灶(25/70,37%,而8/91,17%,p = 0.005)。伴有簇状钙化的毛刺状病灶发生恶性病变的风险最高(6/11,54%)。年龄小于50岁的女性中16/87个病灶为恶性疾病,而50岁及以上女性中为25/74(p = 0.04)。五分之一的冰冻切片对诊断没有帮助。四分之一触诊不到的病变中恶性疾病的发生率与报道的可触及乳腺肿瘤的发生率相似,但诊断时转移明显较少见(30% 对比50%)。
当前应用的乳腺钼靶标准对50岁以下患者特别有帮助。